Explore the clinical trial results for XHANCE

XHANCE was studied in two Phase 3 pivotal trials and two Phase 3 open-label trials1-4

XHANCE was evaluated in NAVIGATE I and NAVIGATE II: Two similar Phase 3 pivotal randomized, placebo-controlled multicenter studies (N=646).1,3

Learn more

Improvement in congestion and other defining nasal symptoms

Patients using XHANCE reported improvement in congestion (coprimary endpoint) and the other 3 defining nasal symptoms.1,3

Learn more

Reductions in bilateral polyp grade

XHANCE reduced bilateral polyp grade (coprimary endpoint), with up to 28% of patients achieving total polyp elimination.1,3

Learn more

~90% of patients using XHANCE reported overall improvement2

Two-thirds of patients reported a Patient Global Impression of Change (PGIC) of “much improved” or “very much improved.”3

Learn more

Exhalation helps deliver medication high and deep into the nasal passages.1,2

References:
  1. Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2017.
  2. Data on file. OptiNose US, Inc.
  3. Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: randomized double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis. J Allergy Clin Immunol. 2018; In press.
  4. Palmer JN, Jacobson KW, Messina JC, Kosik-Gonzalez C, Djupesland PG, Mahmoud RA. EXHANCE-12: 1-year study of the exhalation delivery system with fluticasone (EDS-FLU) in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2018; In press.